Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates
April 18 2024 - 11:00AM
Recor Medical Announces First Cases of Paradise Ultrasound Renal
Denervation Therapy in the United Arab Emirates
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka
Medical Devices Co., Ltd. (“Otsuka Medical Devices”), announce the
first commercial uses of Recor’s Paradise™ Ultrasound Renal
Denervation (uRDN) system for the treatment of hypertension in the
United Arab Emirates (UAE). Three cases were performed at Al
Qassimi Hospital in Sharjah by Dr. Arif Al Nooryani and Dr. Loai
Mousa as second operator.
The Paradise uRDN system is a first-of-its-kind ultrasound-based
renal denervation (RDN) technology designed to lower blood pressure
by denervating overactive sympathetic nerves surrounding the renal
arteries. Paradise uRDN delivers two to three doses of 360-degree
ultrasound energy — lasting seven seconds each — through the main
renal arteries to the surrounding nerves. The Paradise catheter
features the exclusive HydroCooling™ system, which circulates
sterile water through the balloon during the procedure to help cool
and protect the inner layers of the renal artery.
“Around the world, hypertension is one of the most dangerous
cardiovascular conditions, sometimes leading to heart attack and
death. Many people are not even aware of their high blood pressure,
and some patients taking antihypertensive medications remain
uncontrolled or don’t stay adherent. Renal Denervation is a
well-studied treatment and is now recommend in several medical
society guidelines as a therapy option for uncontrolled
hypertension,” said Dr. Arif Al Nooryani, CEO and Head of the
Cardiac Cath Lab at Al Qassimi Hospital Sharjah. “We are
pleased to be the first hospital in the Middle East to offer
ultrasound renal denervation to our patients.”
“Recor is grateful to Dr. Al Nooryani, Dr. Mousa and Al Qassimi
Hospital for bringing Paradise uRDN therapy to their patients in
the United Arab Emirates,” said Lara Barghout, President and CEO of
Recor Medical. “These first cases in the Middle East are an
important initial step toward reaching the many physicians and
patients in the region who are looking for another treatment option
for uncontrolled hypertension.”
Hypertension is the leading contributor to disease burden
worldwide, resulting in increased cardiovascular morbidity and
mortality, poorer quality of life, and higher costs to health
systems. About one-third of the patients treated for hypertension
remain uncontrolled despite lifestyle changes and taking more than
three medications. The Paradise uRDN system is an adjunct treatment
option for patients who have been unable to achieve blood pressure
goals with standard lifestyle changes and oral medications.
The Paradise uRDN system was tested through Recor’s RADIANCE
Global Program of three rigorous prospectively powered and
sham-controlled randomized controlled clinical trials: RADIANCE-HTN
TRIO, which studied patients with resistant hypertension, and
RADIANCE-HTN SOLO and RADIANCE II, which studied patients with
mild-to-moderate hypertension. Each trial successfully met its
prespecified primary efficacy endpoint, showing statistically
significant and clinically meaningful blood pressure reductions
compared to a sham arm and favorable safety profiles.
About Recor Medical, Inc.Recor Medical, headquartered in
Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical
Devices Co., Ltd., is a medical technology company focused on
transforming the management of hypertension. Recor has pioneered
the use of the Paradise Ultrasound Renal Denervation system for the
treatment of hypertension. The Paradise system is an
investigational device in Japan, is FDA approved in the United
States, and bears the CE mark. Recor has reported positive outcomes
in three independent, randomized, sham-controlled studies of the
Paradise system in patients with mild-to-moderate and resistant
hypertension. In addition, Recor has begun the Global Paradise
System (“GPS”) Registry in the European Union and the UK, with
plans to expand globally.
http://www.recormedical.com/
About Otsuka Medical DevicesOtsuka Medical Devices Co.,
Ltd. engages in the global development and commercialization of
medical devices that provide new therapeutic options in areas where
patient needs cannot be met through pharmaceutical or other
conventional treatment. Otsuka Medical Devices is a subsidiary of
Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare
company listed on the Tokyo Stock Exchange (JP 4578).
https://www.omd.otsuka.com/en/
# # #
Media Contact:Lisa OwensThe Mullings
Grouplowens@mullingsgroup.com+1-210-601-6647
- Paradise™ Ultrasound Renal Denervation (uRDN) system for the
treatment of hypertension